New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
07:59 EDTCLDXCelldex reiterated as a Focus Pick at Roth Capital
Roth Capital reiterated Celldex as its Focus Pick citing its broad pipeline and the potential for accelerated approval for either ORR or PFS. Shares are Buy rated with a $16 price target.
News For CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
18:51 EDTCLDXCelldex 7.25M share Secondary priced at $24.00
Subscribe for More Information
February 24, 2015
16:00 EDTCLDXCelldex files to sell 7.25M shares of common stock
Subscribe for More Information
07:15 EDTCLDXCelldex reports Q4 EPS (36c), consensus (35c)
Subscribe for More Information
February 23, 2015
09:25 EDTCLDXOn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTCLDXCelldex rindopepimut receives FDA breakthrough therapy designation
Celldex Therapeutics announced that the FDA has granted rindopepimut Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma, or GBM. This application was based on data from the Phase 2 ReACT study in recurrent GBM, the Phase 2 ACT III study in newly diagnosed GBM and additional supportive Phase 2 studies. An international Phase 3 study of rindopepimut, called ACT IV, in newly diagnosed GBM completed enrollment in December of 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use